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FK506 is a powerful immunosuppressive drug currently in
use that inhibits the activation of several transcription fac-




B) critical for T cell
activation. We show here that, contrary to the situation in T





lymphoid cells such as fibroblasts and renal mesangial cells.





production in vitro and in vivo, in particular in kidney. IL-6
has been shown previously to produce renal abnormalities
in vivo, such as mesangioproliferative glomerulonephritis.
Similar renal abnormalities were also observed in FK506-
treated animals. These results thus suggest a causal rela-



































FK506 is a recently introduced powerful immunosuppressive
drug that exerts its major immunosuppressive effect by inhibit-
ing events including transcriptional activation of several cyto-
kine genes, particularly of the IL-2 gene, which leads to T cell
activation (1). By complexing with an FK506 binding protein
(FKBP12), a member of the immunophilin protein family,







vated phosphatase (2). This calcineurin inhibition in turn
blocks the phosphatase-controlled translocation of transcrip-




-AT to the nucleus; NF-AT is
one of most important transcription factors involved in the ac-
tivation of the IL-2 gene (3, 4). Cyclosporin A (CsA) is an-
other immunosuppressive drug inhibiting this calcineurin/NF-
AT/IL-2 pathway, through complex formation with other
members of the immunophilin family, cyclophilin (2–4).
7FK506 and CsA also inhibit the activation of other tran-









B is an inducible transcription fac-
tor essential for the activation of various cytokines genes, not
only of the IL-2 gene but also of several important inflamma-





a heterodimer containing two subunits of 50 and 65 kD termed
p50 and p65 and preexists in the cytoplasm in an inactive form





















(7–9). In T cells, extracellular stimuli and intracellular signal
transduction pathways similar to those involving calcineurin












B activation. Calcineurin thus appears
to be also a major target for FK506-FKBP12 and CsA-cyclo-













vation (5). By contrast, the results of recent studies indicated













 synthesis (10, 11).
Although the immunosuppressive drug FK506 and CsA
are widely used in clinical transplantation, various side effects
of these drugs, particularly nephrotoxity, limit their usefulness
in widespread applications such as the possible treatment of
autoimmune diseases (12–14). However, it is not clearly estab-
lished yet how these drugs cause renal abnormalities in vivo.





B activation in nonlymphoid cells such as renal





B activation by FK506, FK506 induces the produc-
tion of a pleiotropic inflammatory cytokine, IL-6 (15), in kid-
ney. IL-6 has been shown previously to produce renal
abnormalities in vivo, such as mesangioproliferative glomeru-
lonephritis (16–19). Similar renal abnormalities were also re-
ported in FK506-treated animals (20) and are shown in the
present study. The results of the present study therefore raise




















Mouse L-TK cells were
grown in DME supplemented with 10% FCS. Mouse mesangial cells
(SV40 MES 13, CRL 1927; American Type Culture Collection, Rock-
ville, MD) were grown in a 3:1 mixture of DME and Ham’s F12 me-

















(pp40) coding sequence (21) in a correct orientation into an eukary-
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Abbreviations used in this paper:
 
 CsA, cyclosporin A; EMSA, elec-






otic expression vector driven by a human elongation factor-1 pro-













sion plasmids by the DEAE-dextran method as described previously
(23). 48 h after transfection, cells were treated with FK506 for the
times indicated, and cell extracts were prepared for Western blot
analysis with anti-pp40 antibodies (21). Western blot analysis was car-
ried out by ECL Western blotting (Amersham Corp., Arlington
Heights, IL) according to the manufacturer’s recommendation.
 
Electrophoretic mobility shift assay (EMSA), Northern blot analy-
sis and ELISA.
 
Nuclear extracts were prepared by the method of





probe (GGGATTTTCCC) used in EMSA, and antibody supershift
EMSA were performed as described previously (23, 25). Antibodies




B–p50 and -p65 were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Total RNA was pre-
pared as described previously (26). An entire mouse IL-6 cDNA cod-
ing region (PCR amplified, cloned, and provided by Yoshida and














3 (27) was later used to reprobe the same blot. Levels of IL-6 mRNA
were quantitated by Fujix Bio-image-analyzer (Fuji Film Co., Tokyo,




-actin. IL-6 concentrations in culture su-
pernatants of SV40 MES13 cells were determined with an ELISA kit
(Endogen Inc., Boston, MA) according to the manufacturer’s recom-
mendation. The 24-h trough levels in the whole blood and kidney tis-
sue levels of FK506 were measured by ELISA with an mAb directed
against FK506 (Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan); ex-





Male DDY mice weighing 30 g were divided
into two groups. One group of mice were intramuscularly injected
with 5 mg/kg per d of FK506 (Fujisawa Pharmaceutical Co., for 2, 4, 6,
or 8 wk, and the other group of mice (control group) were injected
with a FK506 vehicle alone. Mice were killed and kidneys were ob-
tained for histological and immunohistochemical studies. FK506 level
monitoring in these mice were performed as described above. IL-6
levels of urine samples from these mice were determined with the ELISA
kit as described above. For light microscopy study, kidney tissues




m) were stained with hematoxylin/eosin or periodic acid-Schiff re-
agents. Immunohistochemical staining of IL-6 was performed as fol-
lows: Kidney tissues were fixed in cold acetone (100%) for 10 min be-
fore staining. Tissue sections were air dried and were incubated with




C and then with rabbit serum (Vector Lab-
oratories Inc., Burlingame, CA) for an additional 30 min to block non-
specific binding. Sections were subsequently incubated with anti–mouse





and, after washing with PBS, were incubated further with biotinated
rabbit anti–goat Ig (Vectastain ABC kit; Vector Laboratories Inc.)
for 30 min. Sections were rinsed again with PBS and were reacted
with avidine peroxidase for 30 min and with diaminobenzidine for 3




The results of several previous studies showed that both CsA




B activation in T cells, presumably
through their actions on calcineurin (5, 6). However, the ef-





in nonlymphoid cells have not been tested previously, and
FK506 and related rapamycin exert various activities in intra-
cellular signal transduction in nonlymphoid cells (29). For
these reasons, we were interested whether these immunosup-




B activation in non-




B-dependent transcriptional activation in fibroblast L-TK
cells. The IL-6 promoter-CAT fusion gene containing the





B-dependent transcriptional activation, as it has been
well established that the activation of the IL-6 promoter by





B (23). The results showed that, while CsA inhibited IL-6
promoter activation induced by IL-1 in a dose-dependent
manner as in T cells, FK506 did not inhibit but rather en-
hanced slightly IL-1–induced IL-6 promoter activation (data
not shown). Furthermore, FK506 itself and the structually re-
lated rapamycin, but not CsA, induced IL-6 promoter activa-





Figure 1. FK506 activates NF-kB in nonlymphoid cells. L-TK (A) or 
mouse mesangial cells (B) were treated for 30 min with IL-1 (21 ng/
ml), LPS (10 mg/ml) or various concentrations of FK506 as indicated, 
and nuclear extracts were prepared and analyzed on EMSA with the 
IL-6 kB motif as a probe. In antibody super-shift EMSA (A, lanes 4–7), 
before to assay, 1 ml of unimmunized sera (lane 5) or anti (a)-NF-
kBp50 (lane 6) or -NF-kBp65 (lane 7) antisera were added to nuclear 
extracts prepared from L-TK cells which were treated for 30 min with 
FK506 (10 mM). NF-kB (p50-p65 heterodimer) and p50 homodimers 
are indicated by arrows.













B motif (data not shown).










vation. Nuclear extracts were prepared from L-TK cells




M FK506 and were analyzed













M FK506 resulted in the appear-

















B-binding activities had mobilities comparable




B (a p65/p50 heterodimer) and p50 ho-




B and p50 homodimers,









). We were also interested to see




B in other types of nonlym-
phoid cells. For this experiment, we selected a mouse renal
mesangial cell line, since this cell line produces IL-6, the gene

















M). In additional experiments, we ana-
lyzed the same cell extracts on EMSA with a probe specific for
the AP-1 transcription factor to test whether FK506 specifi-




B transcription factor. The results



























and its degradation in response to various activators is an es-




B activation (8). An expression








 (pp40) was transfected into L-TK




M FK506 for various
times; cell extracts were subjected to Western blot analysis














activators such as IL-1.
The above results clearly showed that FK506 activates NF-kB
in nonlymphoid fibroblastic and mesangial cell lines. Since
renal mesangial cells have been shown previously to produce
IL-6 (16), we examined whether this FK506-induced NF-kB
activation leads to the induction of endogeneous IL-6 gene ex-
pression and to IL-6 production. After exposure of mesangial
cells with 0.5 or 10 mM FK506 for various times, levels of IL-6
mRNA and IL-6 proteins secreted in culture supernatants
were analyzed with Northern blot analysis and ELISA, respec-
tively. As shown in Fig. 3, the exposure of mesangial cells to
0.5 mM FK506 resulted in the induction of endogeneous IL-6
gene expression as well as IL-6 production.
The results that FK506 induces IL-6 gene expression and
IL-6 production through NF-kB activation in vitro prompted
us to examine whether FK506 also induces IL-6 production in
vivo. Furthermore, since abnormal IL-6 production in vivo has
been shown previously to produce renal abnormalities such as
mesangioproliferative glomerulonephritis (16–19) and since
similar renal abnormalities have also been reported in FK506
treated animals (20), it is of interest to investigate a possible
causal relationship between FK506-induced NF-kB activation
and FK506-induced renal abnormalities. We first quantitated
Figure 2. FK506 induces IkBa degradation. L-TK cells were trans-
fected with an avian IkBa expression vector (10 mg) and were then 
untreated (Control) or treated with FK506 (10 mM) for various times 
as indicated. Cell extracts were subjected to Western blot analysis 
with anti-avian IkBa sera. The arrow indicates IkBa.
Figure 3. FK506 induces IL-6 gene expression and IL-6 production in 
mesangial cells in vitro. (A and B) The induction of endogeneous 
IL-6 gene expression. Mouse mesangial cells were untreated (C), or 
treated with either LPS (10 mg/ml) or FK506 (0.5 and 10 mM) for 12 h 
(A), or were treated with 10 mM FK506 for various times (B), as indi-
cated. Total cellular RNA (20 mg) was prepared and hybridized with 
mouse IL-6 cDNA and human b-actin probes. (C) The induction of 
IL-6 production. Mesangial cells were untreated (cont) or treated 
with FK506 (0.5 mM, open bar; 10 mM, hatched bar) for various times 
as indicated, and concentrations of IL-6 proteins secreted into culture 
supernatants were quantitated with ELISA.
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FK506 levels in whole blood (trough) and tissues, particularly
in kidneys, after FK506 administration in mice to see what
trough FK506 levels are observed, or whether tissue FK506
levels observed are comparable to FK506 concentrations effec-
tive for NF-kB activation in vitro (. 0.1 mM or 82 ng/ml, see
Figs. 1 and 3). With the FK506 dose of 0.5 mg/kg per d, which
is close to the clinical dose of 0.1–0.2 mg/kg per d in humans,
we observed the mean trough level of 4.8 ng/ml and the kidney
tissue level of . 150 ng/g of tissue after 8 wk of FK506 admin-
istration (data not shown). This tissue FK506 level in kidney
might be sufficient for NF-kB activation in vivo. However, the
results of previous clinical studies indicated that renal toxicity
is more frequent in patients with FK506 trough levels higher
than 20 ng/ml (12). We therefore tested a higher FK506 admin-
istration dose (5 mg/kg per d). As shown in Fig. 4, the trough
and kidney tissue FK506 levels were 20–60 ng/ml and 250–600
ng/g of tissue, respectively, after 8 wk of this high FK506 dose.
We therefore adopted this FK506 dose in the subsequent in
vivo study to study FK506-mediated IL-6 production in vivo
and FK506-induced renal abnormalities or toxicity. The results
shown in Fig. 4, in addition, indicate that tissue FK506 levels
are much higher than trough FK506 levels. These results are in
good agreement with those of the previous preclinical and clin-
ical studies (30) and suggest that FK506 tends to accumulate in
tissues, presumably due to its lipophilic nature.
Since IL-6 production in vivo, in particular in kidney, is ex-
pected to increase urinary IL-6 levels, we quantitated urinary
IL-6 levels of mice treated with FK 506 (5 mg/kg per d) for var-
ious periodes. As shown in Fig. 5, FK506 treatment resulted in
a significant increase in urinary IL-6 levels. To further verify
that FK506 induces IL-6 production in vivo, we performed im-
munohistochemical analysis of kidney tissue sections from
mice treated with FK506 for 8 wk. The results are shown in
Fig. 6. While we could not detect significant IL-6 staining in
kidney tissues from control mice (Fig. 6 A), in agreement with
the lack of detectable IL-6 in urine samples from these mice
(Fig. 5), significant staining of IL-6 in kidney tissues from mice
treated with FK506 was observed: in particular, mesangial cells
(Fig. 6 C) and, to a lesser extent, tubular cells (Fig. 6 B)
showed a strong IL-6 staining.
The major histological abnormalities observed in the kid-
neys of FK506-treated mice were mesangial cell proliferation
and an increase in mesangial matrix (Fig. 7 B), which are sug-
gestive of mesangioproliferative glomerulonephritis, and
foamy vacuolization of proximal tubular cells (tubular vacu-
olization) (Fig. 7 C). These histological abnormalities were
also noted in previous studies (20, 31, 32).
Discussion
FK506, a most powerful immunosuppressant currently used,
inhibits the activation of several transcription factors involved
in cytokine gene expression in T cells, including NF-kB. The
results presented in this paper, on the contrary, show that
FK506 activates NF-kB through IkBa degradation in nonlym-
phoid cells (Figs. 1 and 2) and that this FK506-induced NF-kB
activation results in efficient induction of IL-6 production in
vitro and in vivo (Figs. 3, 5, and 6). Although these results indi-
cate that signal transduction pathways leading to NF-kB acti-
vation in lymphoid cells and nonlymphoid cells are different,
they, more importantly, raise two critical questions. One is
how FK506 activates NF-kB. The other is what are the clinical
implications of in vivo FK506-mediated IL-6 production, par-
ticularly in kidney.
Diverse stimuli activate NF-kB through IkBa degradation,
and reactive oxygene intermediates have been implicated as a
common intracellular messenger in signal transduction leading
to IkBa degradation, as NF-kB activation as well as IkBa deg-
radation is blocked by antioxidants such as N-acetylcycteine
(33). The results that FK506 activates NF-kB through IkBa
degradation (Figs. 1 and 2) and that this FK506-induced IkBa
degradation and NF-kB activation is blocked in the presence
Figure 4. Whole blood and tissue FK506 concentrations after FK506 
administration. Mice were intramuscularly injected with 5 mg/kg per 
d of FK506 for 2, 4, 6, or 8 wk, and whole blood (trough, ng/ml; 
shaded bar) and tissue (ng/g of tissue; hatched bar) FK506 levels were 
determined with ELISA.
Figure 5. Enhanced urinary IL-6 excretion after FK506 treatment. 
Mice were intramuscularly injected with 5 mg/kg per d of FK506 for 
2, 4, 6, or 8 wk or with a FK506 vehicle alone (control) as described in 
Methods. Urine samples were collected from these mice, and IL-6 
concentrations were determined with ELISA.
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of N-acetylcycteine (unpublished data), therefore, indicate
that FK506 uses a similar physiological signal transduction
pathway involving reactive oxygene intermediates and leading
to IkBa degradation. We also observed that FK506 activates
MAP kinase (unpublished data), which is also activated by
various NF-kB activating agents including IL-1 and LPS (34).
This again indicates that FK506 can use physiological cellular
signal transduction pathways. However, we do not know at
present what cellular signal transduction pathways are used by
FK506 for NF-kB activation in nonlymphoid cells. Calcineurin
is apparently not involved in this FK506-induced NF-kB acti-
vation in nonlymphoid cells, since both of CsA and FK506, but
not rapamycin, inhibit calcineurin activity (2). Another possi-
ble candidate is c-Raf which has been recently shown to inter-
Figure 6. Immunohistochemical detection of IL-6 proteins in kidney 
of FK506-treated mice. Kidney tissue sections were prepared from 
control mice (A) or from mice treated with FK506 (5 mg/kg per d) for 
8 wk (B and C) as described in Methods. Sections were then pro-
cessed for immunohistochemistry. Original magnification: A and B, 
3100; C, 3400.
Figure 7. Histopathological abnormalities in kidney of FK506-
treated mice. Kidney tissue sections from control mice (A) or from 
mice treated with FK506 (5 mg/kg per d) for 8 wk (B and C) were 
stained with periodic acid-Schiff reagents (A and B) or hematoxylin/
eosin (C). Original magnification, 3200.
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act with FK506 through an unidentified FK506 binding protein
(35) and has been implicated in NF-kB activation (36). It is
also possible that FK506 activates NF-kB through its actions
on a calcium release channel (37). Further work is clearly re-
quired to identify FK506 binding proteins and cellullar factors
involved in FK506-induced NF-kB activation.
Although FK506 is a powerful immunosuppressant, its use-
fulness as an immunosuppressant and its potential clinical ap-
plications to other diseases such as rheumatoid arthritis is
hampered by its side effects, in particular its nephrotoxity (12–
14). Major histopathological abnormalities observed in kidney
after FK506 treatment are mesangial cell proliferation, mesan-
gial matrix increase, and tubular vacuolization (20, 31, 32), as
also shown in this study (Fig. 7). It is not, however, clear how
FK506 produces these renal abnormalities. The present study
showed that as little as 0.1 mM of FK506 effectively activates
NF-kB in nonlymphoid cells, such as renal mesangial cells
(Fig. 1). NF-kB is an important transcription factor involved in
the activation of several inflammatory cytokine genes includ-
ing the IL-6 gene (9). In particular, NF-kB activation is essen-
tial for IL-6 gene expression as shown in in vitro (23) and in
vivo knockout mice (38) studies. We indeed showed that
FK506 induces IL-6 production in mesangial cells (Fig. 3) and
observed IL-6 production in kidney after FK506 treatment of
mice (Figs. 5 and 6). IL-6 has been shown previously to induce
mesangial cell proliferation and matrix increase in vitro (16)
and to produce renal abnormalities such as mesangioprolifera-
tive glomerulonephritis in vivo (16-19). Thus, IL-6 production
in kidney induced by FK506 through NF-kB activation ap-
pears to be responsible for similar renal abnormalities (mesan-
gioproliferative glomerulonephritis) observed in FK506-
treated animals.
In the present in vivo study, we adopted the high FK506
dose (5 mg/kg per d) to study FK506 renal toxicity (12). While
this FK506 dose is much higher than the clinical dose in human
(0.1–0.2 mg/kg per d), several observations suggest that suffi-
cient FK506 accumulates to activate NF-kB and to cause renal
abnormalities after prolonged FK506 treatment even with low
FK506 doses. First, as shown in Fig. 4 as well as reported previ-
ously (30), FK506 has a tendency to accumulate in tissues due
to its lipophilic nature. We indeed observed FK506 tissue lev-
els of as high as 150 ng/g tissue after 8 wk of FK506 treatment
with the FK506 dose of 0.5 mg/kg per d (data not shown). Sec-
ond, different types of cells show different sensitivity to
FK506-induced NF-kB activation and as little as 0.1 mM (82
ng/ml) FK506 is sufficient for NF-kB activation in renal me-
sangial cells (Fig. 1). Third, it has been reported that renal ab-
normalities are late onset (4–8 wk) in clinical studies in which
FK506 doses of 0.15–0.3 mg/kg per d were used (12, 31).
A possible causative relationship of the present finding to
other FK506-mediated renal abnormalities, such as tubular
vacuolization (Fig. 7), is not clear at present, though we also
detected IL-6 in renal tubular cells (Fig. 6). Since CsA, which
cannot activate but rather inhibits NF-kB, has been also re-
ported to produce similar tubular cell abnormalities but not
mesangioproliferative glomerulonephritis (32, 39), it is more
likely that different mechanisms common to FK506 and CsA
are probably involved in this type of renal abnormality (40).
In summary, the present study shows FK506-mediated
NF-kB activation and IL-6 production, and further implicates
its relationship to some of FK506-induced nephropathy. It is,
therefore, possible that in the future the development of effec-
tive NF-kB inhibitors will allow more widespread clinical ap-
plications of this immunosupressive drug.
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